ArticleEye and vision (London, England)2018
Evaluation of markers of outcome in real-world treatment of diabetic macular edema.
Article in Eye and vision (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Association of early anti-VEGF Therapy anatomical response with renal function and OCT biomarkers in diabetic macular edema.BMC ophthalmology · 2026Article
- Early dynamic response on spectral-domain OCT predicts long-term visual outcome in diabetic macular edema treated with aflibercept.BMC ophthalmology · 2026Article
- Biomarkers of Diabetic Macular Edema on Optical Coherence Tomography After Cataract Surgery.Journal of vitreoretinal diseases · 2026Article
- Effect of optical coherence tomography biomarkers on treatment outcomes in patients with diabetic macular edema.International ophthalmology · 2026Article
- Inflammatory Biomarkers in Diabetic Macular Edema.Journal of clinical medicine · 2026Review
- Evaluating the long-term predictive value of macular thickness fluctuations on diabetic macular oedema response to anti-VEGF treatment.Eye (London, England) · 2025Article
- The Ellipsoid Zone Is a Structural Biomarker for Visual Outcomes in Diabetic Macular Edema and Macular Hole Management.Vision (Basel, Switzerland) · 2025Article
- Intravitreal aflibercept for diabetic macular edema: structural and functional improvements.Frontiers in medicine · 2025Article
- Enhancing Diabetic Macular Edema Treatment Outcomes: Exploring the ESASO Classification and Structural OCT Biomarkers.Ophthalmology and therapy · 2024Article
- Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience.Ophthalmology and therapy · 2023Article
- OCT biomarkers as predictors of visual improvement in diabetic macular edema eyes receiving dexamethasone implants.International journal of retina and vitreous · 2023Article
- Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice.International journal of retina and vitreous · 2023Article
- Anatomic Biomarkers of Macular Edema Associated with Retinal Vein Occlusion.Ophthalmology. Retina · 2022Article
- Fluctuations in macular thickness in patients with diabetic macular oedema treated with anti-vascular endothelial growth factor agents.Eye (London, England) · 2022Article
- Optical Coherence Tomography Anatomic and Temporal Biomarkers in Uveitic Macular Edema.American journal of ophthalmology · 2022Article
- Diabetic Retinopathy and Diabetic Macular Edema in People With Early-Onset Diabetes.Clinical diabetes : a publication of the American Diabetes Association · 2022Article
- Intracystic hyperreflective material in centre-involving diabetic macular oedema.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Prognostic biomarkers of chronic diabetic macular edema treated with a fiuocinolone acetonide intravitreal implant.Medical hypothesis, discovery & innovation ophthalmology journal · 2021Article
- Short-Term Outcomes of Refractory Diabetic Macular Edema Switch From Ranibizumab to Dexamethasone Implant and the Influential Factors: A Retrospective Real World Experience.Frontiers in medicine · 2021Article
- Age, Initial Central Retinal Thickness, and OCT Biomarkers Have an Influence on the Outcome of Diabetic Macular Edema Treated With Ranibizumab- Tri-center 12-Month Treat-and-Extend Study.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate short-term markers of outcome in diabetic macular edema (DME).
methodsProspective interventional case series included 122 eyes of 122 patients with recently diagnosed DME. Eyes were treated with a 3-monthly loading dose of ranibizumab or aflibercept and pro re nata thereafter. Serial enhanced deep imaging SD-OCT high resolution scans were used to measure subfoveal choroidal thickness (SFCT) and central retinal thickness (CRT). Anatomic (10% CRT decrease) and functional responses (best corrected visual acuity, BCVA gain ≥5 letters) were assessed at 3 months and 6 months using univariate and multivariate analyses. Parameters tested were gender, duration of diabetes, HbA1c, hypertension, CRT, SFCT, BCVA, ellipsoid zone (EZ) status, subfoveal neuroretinal detachment (SND), anti-VEGF used and laser naivety. A logistic regression model was applied to find independent markers outcome.
resultsBCVA increased, CRT and SFCT decreased at 3 months and 6 months. Good metabolic control (
conclusionThe presence of SND predicts anatomic response only, while an intact EZ is critical to achieve a good functional outcome in DME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.